VX-984 is a selective inhibitor of non-homologous end joining, with possible preferential activity in transformed cells.

Khan, Atif J; Misenko, Sarah M; Thandoni, Aditya; Schiff, Devora; Jhawar, Sachin R; Bunting, Samuel F; Haffty, Bruce G.

Afiliação

Khan AJ; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10011, USA.
Misenko SM; Department of Radiation Oncology, Rutgers-Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA.
Thandoni A; Department of Molecular Biology and Biochemistry, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.
Schiff D; Department of Radiation Oncology, Rutgers-Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA.
Jhawar SR; Department of Radiation Oncology, Rutgers-Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA.
Bunting SF; Department of Radiation Oncology, Rutgers-Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA.
Haffty BG; Department of Molecular Biology and Biochemistry, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.

Oncotarget ; 9(40): 25833-25841, 2018 May 25.

Article em En | MEDLINE | ID: mdl-29899825